Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute
Retrieved on:
Thursday, June 23, 2022
Name, FDA, Approximation error, Safety, WHO, U.S. Public Health Service reorganizations of 1966–1973, DSI, Regulation of tobacco by the U.S. Food and Drug Administration, LCDR, Drug Safety, Fire Safety Evaluation System, Health Canada, Brand Institute, AMA, Risk management, Food, EMA, Technical support, OSE, ODS, Division, Medical device, Epidemiology
MIAMI, June 23, 2022 /PRNewswire/ -- Brand Institute , the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute.
Key Points:
- MIAMI, June 23, 2022 /PRNewswire/ -- Brand Institute , the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute.
- Dr. Roselle joined Drug Safety Institute (DSI) as Managing Director of U.S. Regulatory Affairs in May 2007, and later as Vice President, Global Regulatory Affairs in 2012.
- Dr. Roselle oversees all U.S. brand nomenclature safety assessments and FDA name submissions.
- Drug Safety Institute (DSI) is a wholly owned subsidiary of Brand Institute that provides Brand Institute's healthcare clients with industry-leading guidance pertaining to drug name safety, packaging, and labeling.